As the care of children with brain tumors evolves, there is recognition that despite advances in surgery, chemotherapy and radiation therapy, there are clear needs to explore other options and to create mechanisms where new therapeutic approaches can be assessed carefully and expeditiously. Over the past 2 decades, multiple clinical trials consortia have been developed …
Dr. Roger J. Packer The Childhood Brain Tumor Foundation was pleased to be a Silver Sponsor for the comprehensive 17th International Symposium on Pediatric Neuro-Oncology. Our Neurotransmitter Fall-Winter edition will cover other topics from the other conference. This summary covers a topic from Family Day and Educational Day, held June 11, 2016, related to molecular …
The Childhood Brain Tumor Foundation is pleased to be a Silver sponsor for the 19th International Symposium on Pediatric Neuro-Oncology. Meeting to be held, June 21 to June 24, 2020 in Karuizawa, Nagono, Japan. As always the ISPNO brings together clinicians, researchers, allied health professionals, and experts.
Dr. Anna Marie Kenney, Memorial Sloan Kettering Cancer Center, New York The Childhood Brain Tumor Foundation generously provided support to my lab at Memorial Sloan-Kettering to conduct basic studies of cell biological events that may contribute to medulloblastoma occurrence and growth. Our studies were called “mRNA translation machinery in medulloblastoma”. We used a combination of …
Abstract: CD133+ subpopulations of cells in glioblastoma (GBM) show in vivo resistance to treatment with radiation and temozolomide, and are thought to contribute to therapy evasion and tumor recurrence. Frequent hyperactivation of the MAPK pathway in GBM has prompted the clinical evaluation of several pharmacological MAPK pathway inhibitors for the treatment of GBM. Here we …
John Y.H. Kim, MD, Baylor College of Medicine, Houston, TX Pediatrics became the focus of my clinical interests because of its intrinsic orientation toward developmental issues. I have since had the great fortune of serving children and their families who have charged me with my life’s work. No group of patients and families appeared to …
Gary Tye, M.D., Virginia Commonwealth University In my practice as a pediatric neurosurgeon I see children afflicted with brain tumors on a regular basis, either for surgery or in the many required follow-up visits. Despite our best standards of care, many of these children, assuming they survive their cancer, may suffer severe developmental and cognitive …
A new protocol is open at the Pediatric Oncology Branch of the National Cancer Institute for children, ages 8 to 17 years, who have had a brain tumor that was treated with radiation at least 2 years ago. This study is evaluating whether a novel home physical activity program improves cognitive late effects, which may …
Daniel W. Lee, MD, University of Virginia Cancer Center Charlottesville One-year study, final summary 2019 Dr. Lee and his lab set out to develop a brand new tool to effectively treat children with DIPG. Using Chimeric Antigen Receptor (CAR) T cells, a therapy he helped pioneer in children with refractory leukemia, Dr. Lee’s lab designed, …
